Crystal Structure of the PTEN Tumor Suppressor Implications for Its Phosphoinositide Phosphatase Activity and Membrane Association

The PTEN tumor suppressor is mutated in diverse human cancers and in hereditary cancer predisposition syndromes. PTEN is a phosphatase that can act on both polypeptide and phosphoinositide substrates in vitro. The PTEN structure reveals a phosphatase domain that is similar to protein phosphatases but has an enlarged active site important for the accommodation of the phosphoinositide substrate. The structure also reveals that PTEN has a C2 domain. The PTEN C2 domain binds phospholipid membranes in vitro, and mutation of basic residues that could mediate this reduces PTEN's membrane affinity and its ability to suppress the growth of glioblastoma tumor cells. The phosphatase and C2 domains associate across an extensive interface, suggesting that the C2 domain may serve to productively position the catalytic domain on the membrane.

[1]  Roger L. Williams,et al.  A ternary metal binding site in the C2 domain of phosphoinositide-specific phospholipase C-delta1. , 1997, Biochemistry.

[2]  W. K. Alfred Yung,et al.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers , 1997, Nature Genetics.

[3]  Roger L. Williams,et al.  Calcium-dependent Membrane Penetration Is a Hallmark of the C2 Domain of Cytosolic Phospholipase A2 Whereas the C2A Domain of Synaptotagmin Binds Membranes Electrostatically* , 1998, The Journal of Biological Chemistry.

[4]  Kenneth M. Yamada,et al.  Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. , 1998, Science.

[5]  W. Cho,et al.  A Structure-Function Study of the C2 Domain of Cytosolic Phospholipase A2 , 1999, The Journal of Biological Chemistry.

[6]  José Luis de la Pompa,et al.  Negative Regulation of PKB/Akt-Dependent Cell Survival by the Tumor Suppressor PTEN , 1998, Cell.

[7]  Roger L. Williams,et al.  Crystal structure of a mammalian phosphoinositide-specific phospholipase Cδ , 1996, Nature.

[8]  A. M. Riley,et al.  Structure of the PH domain from Bruton's tyrosine kinase in complex with inositol 1,3,4,5-tetrakisphosphate. , 1999, Structure.

[9]  R. Jahn,et al.  Calcium-dependent interaction of the cytoplasmic region of synaptotagmin with membranes. Autonomous function of a single C2-homologous domain. , 1994, The Journal of biological chemistry.

[10]  L. Dekker,et al.  Crystal structure of the C2 domain from protein kinase C-delta. , 1998, Structure.

[11]  J. Dixon,et al.  PTEN: a tumour suppressor that functions as a phospholipid phosphatase. , 1999, Trends in cell biology.

[12]  S. Sprang,et al.  Structure of the protein kinase Cbeta phospholipid-binding C2 domain complexed with Ca2+. , 1998, Structure.

[13]  Jack E. Dixon,et al.  Crystal Structure of the Dual Specificity Protein Phosphatase VHR , 1996, Science.

[14]  M. Wigler,et al.  P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[15]  D T Jones,et al.  Protein fold recognition by sequence threading: tools and assessment techniques , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[17]  W. Cavenee,et al.  Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Tomohiko Maehama,et al.  The Tumor Suppressor, PTEN/MMAC1, Dephosphorylates the Lipid Second Messenger, Phosphatidylinositol 3,4,5-Trisphosphate* , 1998, The Journal of Biological Chemistry.

[19]  T. Mak,et al.  High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice , 1998, Current Biology.

[20]  E. Fauman,et al.  Crystal structure of Yersinia protein tyrosine phosphatase at 2.5 Å and the complex with tungstate , 1994, Nature.

[21]  T. Südhof,et al.  A single C2 domain from synaptotagmin I is sufficient for high affinity Ca2+/phospholipid binding. , 1993, The Journal of biological chemistry.

[22]  W. Wooster,et al.  Crystal structure of , 2005 .

[23]  D. Barford,et al.  Structural basis for phosphotyrosine peptide recognition by protein tyrosine phosphatase 1B. , 1995, Science.

[24]  G. Mills,et al.  MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. , 1997, Cancer research.

[25]  Thomas L. Madden,et al.  Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. , 1997, Nucleic acids research.

[26]  D. Barford,et al.  Crystal structure of human protein tyrosine phosphatase 1B. , 1994, Science.

[27]  Hong Sun,et al.  PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[28]  K. Mikoshiba,et al.  Phospholipid Composition Dependence of Ca-dependent Phospholipid Binding to the C2A Domain of Synaptotagmin IV (*) , 1996, The Journal of Biological Chemistry.

[29]  P C Sternweis,et al.  Regulation of eukaryotic phosphatidylinositol-specific phospholipase C and phospholipase D. , 1997, Annual review of biochemistry.

[30]  J. Zou,et al.  Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.

[31]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[32]  J. Puck,et al.  Inherited Human Caspase 10 Mutations Underlie Defective Lymphocyte and Dendritic Cell Apoptosis in Autoimmune Lymphoproliferative Syndrome Type II , 1999, Cell.

[33]  H. Wu,et al.  PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[34]  G. Ruvkun,et al.  The C. elegans PTEN homolog, DAF-18, acts in the insulin receptor-like metabolic signaling pathway. , 1998, Molecular cell.

[35]  M. Bycroft,et al.  Crystal Structure of a Calcium-Phospholipid Binding Domain from Cytosolic Phospholipase A2* , 1998, The Journal of Biological Chemistry.

[36]  H. Hanafusa,et al.  The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[37]  M. Wigler,et al.  The lipid phosphatase activity of PTEN is critical for its tumor supressor function. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[38]  T. Südhof,et al.  C2-domains, Structure and Function of a Universal Ca2+-binding Domain* , 1998, The Journal of Biological Chemistry.

[39]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[40]  W. Cavenee,et al.  The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. , 1998, Cancer research.

[41]  Carlos Cordon-Cardo,et al.  Pten is essential for embryonic development and tumour suppression , 1998, Nature Genetics.

[42]  E. Chapman,et al.  Direct Interaction of a Ca2+-binding Loop of Synaptotagmin with Lipid Bilayers* , 1998, The Journal of Biological Chemistry.

[43]  C. Cordon-Cardo,et al.  Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. , 1999, Proceedings of the National Academy of Sciences of the United States of America.